市場調查報告書
商品編碼
1045187

考慮了多發性硬化症的全球市場(2021年版):各類藥物、各給藥途徑、各銷售管道、各地區、各國分析,市場洞察,開發平台,COVID-19影響的市場洞察與預測(2021年∼2026年)

Global Multiple Sclerosis (MS) Market - Analysis By Drug Class, Route of Administration, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Pipeline and Forecast with Impact of COVID-19 (2021-2026)

出版日期: | 出版商: Azoth Analytics | 英文 220 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球多發性硬化症市場規模,2020年估計為260億1,000萬美元。

作為治療選擇的疾病緩解藥物的導入是推動全球多發性硬化症市場成長的關鍵因素。各種技術進步,例如用於有效治療MS的創新單克隆體、免疫調節劑、免疫抑製劑和乾擾素的開發,成為主要的成長誘導因素。此外,全球多發性硬化症市場的成長是由對口服藥物的偏好轉變所推動的。此外,預計管道藥物數量增加將為預測期內的市場擴張提供有利可圖的機會。

本報告提供全球多發性硬化症市場的相關調查,市場分析,市場動態,競爭情形,企業簡介等全面性資訊。

目錄

第1章 調查範圍和調查手法

  • 調查範圍
  • 調查手法
  • 摘要整理

第2章 策略性推薦事項

第3章 多發性硬化症市場:產品預測

第4章 全球多發性硬化症市場:規模與預測

  • 全球多發性硬化症的市場規模:各金額(2016年∼2026年)
  • 對全球多發性硬化症市場的COVID-19影響

第5章 全球多發性硬化症市場區隔:各類藥物,各給藥途徑,各銷售管道

  • 全球多發性硬化症市場競爭模式:各類藥物
    • 免疫調節劑-市場規模與預測(2016年∼2026年)
    • 免疫抑制劑-市場規模與預測(2016年∼2026年)
    • 干擾素-市場規模與預測(2016年∼2026年)
    • 其他-市場規模與預測(2016年∼2026年)
  • 全球多發性硬化症市場競爭模式:各給藥途徑
    • 口服-市場規模與預測(2016年∼2026年)
    • 注射-市場規模與預測(2016年∼2026年)
    • 靜脈內-市場規模與預測(2016年∼2026年)
  • 全球多發性硬化症市場競爭模式:各銷售管道
    • 醫院藥局-市場規模與預測(2016年∼2026年)
    • 零售藥局-市場規模與預測(2016年∼2026年)
    • 線上藥局-市場規模與預測(2016年∼2026年)

第6章 全球多發性硬化症市場:地區分析

  • 全球多發性硬化症市場競爭模式:各地區

第7章 北美的多發性硬化症市場:分析(2016年∼2026年)

  • 北美的多發性硬化症市場:規模與預測(2016年∼2026年)
  • 北美的多發性硬化症市場-著名的企業
  • 市場區隔:各藥物類別(免疫調節劑,免疫抑制劑,干擾素,其他)
  • 市場區隔:各給藥途徑(口服,注射,靜脈內)
  • 市場區隔:各通路(醫院藥局,零售藥局,線上藥局)
  • 北美的多發性硬化症市場:各國分析
  • 北美的多發性硬化症市場的市場機會表:各國,各金額(2026年)
  • 北美的多發性硬化症市場競爭模式:各國
  • 美國的多發性硬化症市場:規模與預測:各金額(2016年∼2026年)
  • 美國的多發性硬化症市場區隔:各類藥物,各給藥途徑,各銷售管道(2016年∼2026年)
  • 加拿大的多發性硬化症市場:規模與預測:各金額(2016年∼2026年)
  • 加拿大的多發性硬化症市場區隔:各類藥物,各給藥途徑,各銷售管道(2016年∼2026年)

第8章 歐洲的多發性硬化症市場:分析(2016年∼2026年)

  • 歐洲的多發性硬化症市場:規模與預測(2016年∼2026年)
  • 歐洲的多發性硬化症市場-著名的企業
  • 市場區隔:各藥物類別(免疫調節劑,免疫抑制劑,干擾素,其他)
  • 市場區隔:各給藥途徑(口服,注射,靜脈內)
  • 市場區隔:各通路(醫院藥局,零售藥局,線上藥局)
  • 歐洲的多發性硬化症市場:各國分析
  • 歐洲的多發性硬化症市場的市場機會表:各國,各金額(2026年)
  • 歐洲的多發性硬化症市場競爭模式:各國
  • 德國的多發性硬化症市場:規模與預測:各金額(2016年∼2026年)
  • 德國的多發性硬化症市場區隔:各類藥物,各給藥途徑,各銷售管道(2016年∼2026年)
  • 英國的多發性硬化症市場:規模與預測:各金額(2016年∼2026年)
  • 英國的多發性硬化症市場區隔:各類藥物,各給藥途徑,各銷售管道(2016年∼2026年)
  • 法國的多發性硬化症市場:規模與預測:各金額(2016年∼2026年)
  • 法國多發性硬化症市場區隔:各類藥物,各給藥途徑,各銷售管道(2016年∼2026年)
  • 義大利的多發性硬化症市場:規模與預測:各金額(2016年∼2026年)
  • 義大利多發性硬化症市場區隔:各類藥物,各給藥途徑,各銷售管道(2016年∼2026年)

第9章 亞太地區的多發性硬化症市場:分析(2016年∼2026年)

  • 亞太地區的多發性硬化症市場:規模與預測:各金額(2016年∼2026年)
  • 亞太地區的多發性硬化症市場-著名的企業
  • 市場區隔:各藥物類別(免疫調節劑,免疫抑制劑,干擾素,其他)
  • 市場區隔:各給藥途徑(口服,注射,靜脈內)
  • 市場區隔:各通路(醫院藥局,零售藥局,線上藥局)
  • 亞太地區的多發性硬化症市場:各國分析
  • 亞太地區的多發性硬化症市場的市場機會表:各國,各金額(2026年)
  • 亞太地區的多發性硬化症市場競爭模式:各國
  • 中國的多發性硬化症市場:規模與預測:各金額(2016年∼2026年)
  • 中國的多發性硬化症市場區隔:各類藥物,各給藥途徑,各銷售管道(2016年∼2026年)
  • 日本的多發性硬化症市場:規模與預測:各金額(2016年∼2026年)
  • 日本的多發性硬化症市場區隔:各類藥物,各給藥途徑,各銷售管道(2016年∼2026年)
  • 印度的多發性硬化症市場:規模與預測:各金額(2016年∼2026年)
  • 印度的多發性硬化症市場區隔:各類藥物,各給藥途徑,各銷售管道(2016年∼2026年)
  • 韓國的多發性硬化症市場:規模與預測:各金額(2016年∼2026年)
  • 韓國的多發性硬化症市場區隔:各類藥物,各給藥途徑,各銷售管道(2016年∼2026年)

第10章 全球多發性硬化症市場動態

  • 促進因素
  • 阻礙因素
  • 趨勢

第11章 市場魅力

  • 全球多發性硬化症市場市場魅力表:各類藥物(2026年)
  • 全球多發性硬化症市場市場魅力表:各給藥途徑(2026年)
  • 全球多發性硬化症市場市場魅力表:各銷售管道(2026年)
  • 全球多發性硬化症市場市場魅力表:各地區(2026年)

第12章 競爭情形

  • 大多發性硬化症企業的產品平台
  • 市場佔有率分析

第13章 企業的分析

  • Bristol-Myers Squibb
  • F. Hoffman-La Roche, Ltd.
  • Pfizer Inc.
  • GlaxoSmithKline
  • Novartis AG
  • Teva Pharmaceuticals Industries Limited
  • BAYER AG
  • Biogen
  • EMD Sereno
  • NervGen Pharma
目錄

Executive Summary

The Global Multiple Sclerosis Market is estimated at USD 26.01 Billion in the year 2020. The introduction of disease-modifying drugs as a treatment option is a key factor that drives the growth of the global multiple sclerosis market. Various technological advancements, such as the development of innovative monoclonal bodies, immuno-modulators, immunosuppressants and interferons for the effective treatment of MS, are acting as major growth-inducing factors. Moreover, the growth of the global multiple sclerosis market is driven by a shift in preference toward oral drugs. Also, an increase in the number of pipeline drugs is anticipated to offer lucrative opportunities for market expansion during the forecast period.

The expansion of the Multiple Sclerosis Market is encouraged by government and non-government organizations. The government and non-governmental organizations support a variety of initiatives and programs to help persons with multiple sclerosis improve their quality of life (MS).

The global multiple sclerosis market size is set to gain traction as many leading pharmaceutical companies are conducting clinical trials to discover innovative and effective therapies for the treatment of this immune disorder. In addition, clinical studies for the treatment of multiple sclerosis are being conducted by several pharmaceutical companies. Companies are working to create novel medicines in multiple sclerosis radiology for patients suffering from the condition which is further driving the growth of the market.

Scope of the Report

  • The report analyses the Multiple Sclerosis Market for the historical period 2016-2020 and the forecast period of 2021-2026.
  • The report analyses the Multiple Sclerosis Market by Value (USD Million).
  • The report analyses the Multiple Sclerosis Market Drug Class (Immunomodulators, Immunosuppressants, Interferons, Others).
  • The report analyses the Multiple Sclerosis Market by Route of Administration (Oral, Injectable, Intravenous).
  • The report analyses the Multiple Sclerosis Market Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy).
  • The Global The report analyses the Multiple Sclerosis Market by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy).
  • Market has been analysed By Region (North America, Europe, Asia Pacific, LAMEA) By Country (United States, Canada, Germany, U.K, France, Italy, China, Japan, India, South Korea).
  • The key insights of the report have been presented through the frameworks of the attractiveness of the market has been presented by region, by Drug Class, by Route of Administration, by Distribution Channel.
  • Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
  • The report tracks competitive developments, strategies, Pipelines and new product development. The companies analysed in the report include Bristol-Myers Squibb, F. Hoffman-La Roche, Ltd., Pfizer Inc., GlaxoSmithKline, Novartis AG, Teva Pharmaceuticals Industries Limited, BAYER AG, Biogen, EMD Sereno, NervGen Pharma.

Key Target Audience

  • Healthcare and Pharmaceutical Companies
  • Consulting and Advisory Firms
  • Government and Policy Makers
  • Regulatory Authorities

Table of Contents

1. Report Scope and Methodology

  • 1.1 Scope of the Report
  • 1.2 Research Methodology
  • 1.3 Executive Summary

2. Strategic Recommendations

3. Multiple Sclerosis Market: Product Outlook

4. Global Multiple Sclerosis Market: Sizing and Forecast

  • 4.1 Global Multiple Sclerosis Market Size, By Value, 2016-2026
  • 4.2 Impact of COVID-19 on Global Multiple Sclerosis Market

5. Global Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel

  • 5.1 Competitive Scenario of Global Multiple Sclerosis Market: By Drug Class
    • 5.1.1 Immunomodulators - Market Size and Forecast (2016-2026)
    • 5.1.2 Immunosuppressants - Market Size and Forecast (2016-2026)
    • 5.1.3 Interferons - Market Size and Forecast (2016-2026)
    • 5.1.4 Others - Market Size and Forecast (2016-2026)
  • 5.2 Competitive Scenario of Global Multiple Sclerosis Market: By Route of Administration
    • 5.2.1 Oral - Market Size and Forecast (2016-2026)
    • 5.2.2 Injectable - Market Size and Forecast (2016-2026)
    • 5.2.3 Intravenous - Market Size and Forecast (2016-2026)
  • 5.3 Competitive Scenario of Global Multiple Sclerosis Market: By Distribution Channel
    • 5.3.1 Hospitals Pharmacy- Market Size and Forecast (2016-2026)
    • 5.3.2 Retail Pharmacy - Market Size and Forecast (2016-2026)
    • 5.3.3 Online Pharmacy - Market Size and Forecast (2016-2026)

6. Global Multiple Sclerosis Market: Regional Analysis

  • 6.1 Competitive Scenario of Global Multiple Sclerosis Market: By Region

7. North America Multiple Sclerosis Market: An Analysis (2016-2026)

  • 7.1 North America Multiple Sclerosis Market: Size and Forecast (2016-2026)
  • 7.2 North America Multiple Sclerosis Market - Prominent Companies
  • 7.3 Market Segmentation By Drug Class (Immunomodulators, Immunosuppressants, Interferons and Others)
  • 7.4 Market Segmentation By Route of Administration (Oral, Injectable, Intravenous)
  • 7.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 7.6 North America Multiple Sclerosis Market: Country Analysis
  • 7.7 Market Opportunity Chart of North America Multiple Sclerosis Market - By Country, By Value, 2026
  • 7.8 Competitive Scenario of North America Multiple Sclerosis Market: By Country
  • 7.9 United States Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
  • 7.10 United States Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
  • 7.11 Canada Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
  • 7.12 Canada Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)

8. Europe Multiple Sclerosis Market: An Analysis (2016-2026)

  • 8.1 Europe Multiple Sclerosis Market: Size and Forecast (2016-2026)
  • 8.2 Europe Multiple Sclerosis Market - Prominent Companies
  • 8.3 Market Segmentation By Drug Class (Immunomodulators, Immunosuppressants, Interferons and Others)
  • 8.4 Market Segmentation By Route of Administration (Oral, Injectable, Intravenous)
  • 8.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 8.6 Europe Multiple Sclerosis Market: Country Analysis
  • 8.7 Market Opportunity Chart of Europe Multiple Sclerosis Market - By Country, By Value, 2026
  • 8.8 Competitive Scenario of Europe Multiple Sclerosis Market: By Country
  • 8.9 Germany Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
  • 8.10 Germany Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
  • 8.11 United Kingdom Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
  • 8.12 United Kingdom Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
  • 8.13 France Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
  • 8.14 France Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
  • 8.15 Italy Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
  • 8.16 Italy Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)

9. Asia Pacific Multiple Sclerosis Market: An Analysis (2016-2026)

  • 9.1 Asia Pacific Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
  • 9.2 Asia Pacific Multiple Sclerosis Market - Prominent Companies
  • 9.3 Market Segmentation By Drug Class (Immunomodulators, Immunosuppressants, Interferons and Others)
  • 9.4 Market Segmentation By Route of Administration (Oral, Injectable, Intravenous)
  • 9.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 9.6 Asia Pacific Multiple Sclerosis Market: Country Analysis
  • 9.7 Market Opportunity Chart Asia Pacific Multiple Sclerosis Market - By Country, By Value, 2026
  • 9.8 Competitive Scenario of Asia Pacific Multiple Sclerosis Market: By Country
  • 9.9 China Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
  • 9.10 China Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)

911 Japan Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value

  • 9.12 Japan Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
  • 9.13 India Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
  • 9.14 India Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
  • 9.15 South Korea Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
  • 9.16 South Korea Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)

10. Global Multiple Sclerosis Market Dynamics

  • 10.1 Drivers
  • 10.2 Restraints
  • 10.3 Trends

11. Market Attractiveness

  • 11.1 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Drug Class, 2026
  • 11.1 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Route of Administration, 2026
  • 11.2 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Distribution Channel, 2026
  • 11.3 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Region, 2026

12. Competitive Landscape

  • 12.1 Product Pipeline of Leading Multiple Sclerosis Companies
  • 12.2 Market Share Analysis

13. Company Analysis

  • 13.1 Bristol-Myers Squibb
  • 13.2 F. Hoffman-La Roche, Ltd.
  • 13.3 Pfizer Inc.
  • 13.4 GlaxoSmithKline
  • 13.5 Novartis AG
  • 13.6 Teva Pharmaceuticals Industries Limited
  • 13.7 BAYER AG
  • 13.8 Biogen
  • 13.9 EMD Sereno
  • 13.10 NervGen Pharma

List of Figures

List of Figures

  • Figure 1: Global Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
  • Figure 2: Global Prevalence of Neurological Disorders, 2015-2019 (In Billions)
  • Figure 3: Global Prevalence of Total Cancer, 2015-2019 (In Millions)
  • Figure 4: World Population 65 Years & Above (% of Total), 2015-2019
  • Figure 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Figure 6: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
  • Figure 7: Global Multiple Sclerosis Market- By Drug Class Market Share, 2020 & 2026
  • Figure 8: Global Multiple Sclerosis Market- By Immunomodulators, By Value (USD Million), 2016-2026
  • Figure 9: Global Multiple Sclerosis Market- By Immunosuppressants, By Value (USD Million), 2016-2026
  • Figure 10: Global Multiple Sclerosis Market- By Interferons, By Value (USD Million), 2016-2026
  • Figure 11: Global Multiple Sclerosis Market- By Others, By Value (USD Million), 2016-2026
  • Figure 12: Global Multiple Sclerosis Market- By Route of Administration Market Share, 2020 & 2026
  • Figure 13: Global Multiple Sclerosis Market- By Oral, By Value (USD Million), 2016-2026
  • Figure 14: Global Multiple Sclerosis Market- By Injectable, By Value (USD Million), 2016-2026
  • Figure 15: Global Multiple Sclerosis Market- By Intravenous, By Value (USD Million), 2016-2026
  • Figure 16: Global Multiple Sclerosis Market- By Distribution Channel Market Share, 2020 & 2026
  • Figure 17: Global Multiple Sclerosis Market- By Hospital Pharmacy, By Value (USD Million), 2016-2026
  • Figure 18: Global Multiple Sclerosis Market- By Retail Pharmacy, By Value (USD Million), 2016-2026
  • Figure 19: Global Multiple Sclerosis Market- By Online Pharmacy, By Value (USD Million), 2016-2026
  • Figure 20: Global Multiple Sclerosis Market- By Region Market Share, 2020 & 2026
  • Figure 21: North America Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
  • Figure 22: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
  • Figure 23: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
  • Figure 24: North America Prevalence of Total Cancer, 2015-2019 (In Millions)
  • Figure 25: North America Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
  • Figure 26: North America Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
  • Figure 27: North America Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
  • Figure 28: Market Opportunity Chart of North America Multiple Sclerosis Market- By Country, By Value (Year 2016-2026)
  • Figure 29: North America Multiple Sclerosis Market- By Country Market Share, 2020 & 2026
  • Figure 30: United States Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
  • Figure 31: United State Prevalence of Neurological Disorders, 2015-2019 (In Millions)
  • Figure 32: United States Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Figure 33: United State Prevalence of Total Cancer, 2015-2019 (In Millions)
  • Figure 34: United States Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
  • Figure 35: United States Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
  • Figure 36: United States Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
  • Figure 37: Canada Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
  • Figure 38: Canada Prevalence of Neurological Disorders, 2015-2019 (In Millions)
  • Figure 39: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Figure 40: Canada Prevalence of Total Cancer, 2015-2019 (In Millions)
  • Figure 41: Canada Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
  • Figure 42: Canada Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
  • Figure 43: Canada Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
  • Figure 44: Europe Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
  • Figure 45: Europe Prevalence of Neurological Disorders, 2015-2019 (In Millions)
  • Figure 46: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Figure 47: Europe Prevalence of Total Cancer, 2015-2019 (In Millions)
  • Figure 48: Europe Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
  • Figure 49: Europe Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
  • Figure 50: Europe Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
  • Figure 51: Market Opportunity Chart of Europe Multiple Sclerosis Market- By Country, By Value (Year 2016-2026)
  • Figure 52: Europe Multiple Sclerosis Market- By Country Market Share, 2020 & 2026
  • Figure 53: Germany Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
  • Figure 54: Germany Prevalence of Neurological Disorders, 2015-2019 (In Millions)
  • Figure 55: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Figure 56: Germany Prevalence of Total Cancer, 2015-2019 (In Millions)
  • Figure 57: Germany Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
  • Figure 58: Germany Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
  • Figure 59: Germany Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
  • Figure 60: United Kingdom Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
  • Figure 61: United Kingdom Prevalence of Neurological Disorders, 2015-2019 (In Millions)
  • Figure 62: United Kingdom Number of people with MS (per 100,000 people), 2017
  • Figure 63: United Kingdom Prevalence of Total Cancer, 2015-2019 (In Millions)
  • Figure 64: United Kingdom Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
  • Figure 65: United Kingdom Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
  • Figure 66: United Kingdom Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
  • Figure 67: France Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
  • Figure 68: France Prevalence of Neurological Disorders, 2015-2019 (In Millions)
  • Figure 69: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Figure 70: France Prevalence of Total Cancer, 2015-2019 (In Millions)
  • Figure 71: France Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
  • Figure 72: France Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
  • Figure 73: France Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
  • Figure 74: Italy Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
  • Figure 75: Italy Prevalence of Neurological Disorders, 2015-2019 (In Millions)
  • Figure 76: Italy Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Figure 77: Italy Prevalence of Total Cancer, 2015-2019 (In Millions)
  • Figure 78: Italy Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
  • Figure 79: Italy Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
  • Figure 80: Italy Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
  • Figure 81: Asia Pacific Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
  • Figure 82: Asia Pacific Prevalence of Neurological Disorders, 2015-2019 (In Millions)
  • Figure 83: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Figure 84: Asia Pacific Prevalence of Total Cancer, 2015-2019 (In Millions)
  • Figure 85: Asia Pacific Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
  • Figure 86: Asia Pacific Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
  • Figure 87: Asia Pacific Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
  • Figure 88: Market Opportunity Chart of APAC Multiple Sclerosis Market- By Country, By Value (Year-2026)
  • Figure 89: APAC Multiple Sclerosis Market- By Country Market Share, 2020 & 2026
  • Figure 90: China Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
  • Figure 91: China Prevalence of Neurological Disorders, 2015-2019 (In Millions)
  • Figure 92: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Figure 93: China Prevalence of Total Cancer, 2015-2019 (In Millions)
  • Figure 94: China Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
  • Figure 95: China Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
  • Figure 96: China Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
  • Figure 97: Japan Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
  • Figure 98: Japan Prevalence of Neurological Disorders, 2015-2019 (In Millions)
  • Figure 99: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
  • Figure 100: Japan Prevalence of Total Cancer, 2015-2019 (In Millions)
  • Figure 101: Japan Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
  • Figure 102: Japan Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
  • Figure 103: Japan Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
  • Figure 104: India Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
  • Figure 105: India Prevalence of Neurological Disorders, 2015-2019 (In Millions)
  • Figure 106: e-pharmacy market in India (USD million)
  • Figure 107: India Prevalence of Total Cancer, 2015-2019 (In Millions)
  • Figure 108: India Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
  • Figure 109: India Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
  • Figure 110: India Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
  • Figure 111: South Korea Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
  • Figure 112: South Korea Prevalence of Neurological Disorders, 2015-2019 (In Millions)
  • Figure 113: South Korea Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Figure 114: South Korea Prevalence of Total Cancer, 2015-2019 (In Millions)
  • Figure 115: South Korea Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
  • Figure 116: South Korea Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
  • Figure 117: South Korea Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
  • Figure 118: Market Attractiveness Chart of Global Multiple Sclerosis Market- By Drug Class (Year-2016-2026)
  • Figure 119: Market Attractiveness Chart of Global Multiple Sclerosis Market- By Route of Administration (Year 2016-2026)
  • Figure 120: Market Attractiveness Chart of Global Multiple Sclerosis Market- By Distribution Channel (Year 2016-2026)
  • Figure 121: Market Attractiveness Chart of Global Multiple Sclerosis Market- By Region (Year 2016-2026)
  • Figure 122: Global Multiple Sclerosis company market share (%), 2020
  • Figure 123: Bristol-Myers Squibb Sales Revenues, 2016-2020 (USD Million)
  • Figure 124: Bristol-Myers Squibb Net Income, 2016-2020 (USD Million)
  • Figure 125: Bristol-Myers Squibb Sales Revenue Split, By Business Segment (%), FY2020
  • Figure 126: Bristol-Myers Squibb Sales Revenue Split, By Geography Segment (%), FY2020
  • Figure 127: F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)
  • Figure 128: F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)
  • Figure 129: F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020
  • Figure 130: F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020
  • Figure 131: Pfizer Inc., Annual Sales Revenue (USD Million), 2016-2020
  • Figure 132: Pfizer Inc., Annual Net Income/Loss (USD Million), 2016-2020
  • Figure 133: Pfizer Inc., sales Revenue, By Geographical Segment (%), FY2020
  • Figure 134: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020
  • Figure 135: GlaxoSmithKline Gross Profit (USD Million), 2016-2020
  • Figure 136: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020
  • Figure 137: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020
  • Figure 138: Novartis Annual Sales Revenue (USD Million), 2016-2020
  • Figure 139: Novartis Annual Net Income/Loss (USD Million), 2016-2020
  • Figure 140: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
  • Figure 141: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
  • Figure 142: Teva Pharmaceutical Industries Ltd. Sales Revenues, 2016-2020 (USD Million)
  • Figure 143: Teva Pharmaceutical Industries Ltd. Net Income, 2016-2020 (USD Million)
  • Figure 144: Teva Pharmaceutical Industries Ltd. sales Revenues, By Business Segment (%) in North America, FY2020
  • Figure 145: Teva Pharmaceutical Industries Ltd. sales Revenue, By Geographical Segment (%), FY2020
  • Figure 146: Bayer Group Sales Revenues, 2016-2020 (USD Million)
  • Figure 147: Bayer Group Net Profit, 2016-2020 (USD Million)
  • Figure 148: Bayer Group, By Business Segment (%), FY2020
  • Figure 149: Bayer Group, By Geographical Segment (%), FY2020
  • Figure 150: Biogen Sales Revenues, 2016-2020 (USD Million)
  • Figure 151: Biogen Net Profit, 2016-2020 (USD Million)
  • Figure 152: Biogen, By Business Segment (%), FY2020
  • Figure 153: Biogen, By Geographical Segment (%), FY2020

List of Tables

Table A Product Pipeline of Leading Multiple Sclerosis Companies

Table B Product Pipeline of Leading Multiple Sclerosis Companies

Table C Product Pipeline of Leading Multiple Sclerosis Companies - NervGen Pharma